Werewolf Therapeutics Q2 net loss $18M; WTX-124 data on track for Q4 2025

Werewolf Therapeutics, Inc.

Cash $77.6M as of June 30, 2025, providing runway into Q4 2026.
Net loss $18.0M for Q2 2025 vs $17.2M in Q2 2024; R&D $13.1M, G&A $4.4M.
WTX-124 Phase 1/1b interim data expected Q4 2025 in melanoma and renal cell carcinoma.
Planning FDA engagement in H2 2025 to discuss registrational pathway for cutaneous melanoma.
New candidate WTX-1011 (anti-STEAP1 T-cell engager) announced; additional candidate expected by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.